Jerel Banks | BiotechTV

top of page

ASGCT 2026: Benitec Biopharma presented a clinical update of its lead DNA-directed RNA interference program targeting Oculopharyngeal Muscular Dystrophy (OPMD)

Executive Chair & CEO Jerel Banks describes how Benitec is programing the body to create its own internal continuous RNAi factory to treat this disease. With this clinical data in hand, Benitec plans to meet with FDA about the design of a pivotal trial. Coverage brought to you by

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

ASGCT 2026: Benitec Biopharma presented a clinical update of its lead DNA-directed RNA interference program targeting Oculopharyngeal Muscular Dystrophy (OPMD)

Follow BiotechTV

Sponsors

Sponsor Spotlight